Razo

Product Description

Razo is a pharmaceutical preparation containing Rabeprazole as its active component. This medication falls under the category of proton pump inhibitors (PPIs) and is primarily indicated for managing disorders associated with excessive gastric acid secretion.

Therapeutic Applications

Razo is clinically indicated for:

• Gastroesophageal reflux disease (GERD): Alleviates symptoms including heartburn, acid reflux, and regurgitation through gastric acid suppression.
• Gastric ulceration: Facilitates healing and prevents recurrence of stomach ulcers.
• Duodenal ulceration: Promotes healing and prevents recurrence of ulcers in the duodenum.
• Helicobacter pylori eradication: Employed as part of combination therapy for eliminating H. pylori infections associated with peptic ulcer disease.

Administration Guidelines

Razo tablets should be administered orally, typically once daily prior to breakfast. The tablet must be swallowed intact with water, without crushing or chewing. Adhere to the treatment duration specified by your healthcare provider.

Mechanism of Action

Razo exerts its therapeutic effect by selectively inhibiting the hydrogen-potassium ATPase enzyme system (proton pump) in gastric parietal cells. This action suppresses gastric acid secretion, thereby providing symptomatic relief and promoting mucosal healing.

Therapeutic Advantages

Key clinical benefits of Razo include:

• Effective gastric acid suppression: Significantly reduces hydrochloric acid production, alleviating symptoms of hyperacidity including heartburn and reflux.
• Ulcer management: Enhances healing and prevents recurrence of both gastric and duodenal ulcers.
• Anti-H. pylori activity: Contributes to successful eradication of H. pylori when used in combination regimens.

Adverse Effects

Common adverse reactions may include:

• Cephalalgia (headache)
• Diarrhea
• Nausea
• Abdominal discomfort
• Flatulence

These effects are typically transient and mild in nature. Persistent or severe symptoms warrant medical consultation.

Dosage Protocol

The therapeutic regimen should be individualized based on clinical indication and patient characteristics. Standard dosing involves administration of one 10 mg tablet daily before breakfast. Treatment duration should be determined by a qualified healthcare practitioner.

Precautions and Contraindications

Important safety considerations:

• Hypersensitivity: Contraindicated in patients with known hypersensitivity to Rabeprazole or other PPIs.
• Drug interactions: Potential interactions with medications such as warfarin and atazanavir necessitate comprehensive medication review.
• Special populations: Medical consultation is essential for pregnant, lactating, or childbearing-age women.
• Long-term therapy: Extended PPI use may be associated with increased risk of infections, osteoporotic fractures, and micronutrient deficiencies (particularly vitamin B12). Regular clinical monitoring is advised.

Storage Requirements

Maintain Razo tablets in their original packaging at controlled room temperature (15-30°C), protected from light and moisture. Keep out of reach of pediatric patients and animals. Do not administer beyond the expiration date indicated on packaging. Proper disposal methods should be followed for expired or unused medication, as advised by healthcare professionals or pharmacists. For more information on medication procurement, see our guide on medication acquisition options.